+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06907342

Feasibility Study of Precision Medicine to Guide Oxaliplatin or Irinotecan Chemotherapy for Adults with Metastatic Colorectal Cancer

Led by St. Olavs Hospital · Updated on 2026-07-20

148

Participants Needed

1

Research Sites

665 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a precision medicine approach to select the most suitable chemotherapy regimen for adults aged 18 and older with metastatic colorectal cancer that is microsatellite stable or proficient mismatch repair. This study aims to test the feasibility of using patient-derived tumouroids to guide the choice between oxaliplatin-based and irinotecan-based chemotherapy, focusing on incurable or unresectable cancer. The trial is a phase II, single-arm, single-center study designed to improve treatment decisions within the standard care framework. Participants receive chemotherapy regimens guided by tumouroid response reports derived from biopsies of their tumors. The two main treatment options being compared are FOLFOX oxaliplatin-based and FOLFIRI irinotecan-based, both possibly combined with antibodies. Treatment allocation is based on the functional precision medicine platforms readout, with chemotherapy scheduled within 28 days of referral according to national guidelines. The treatment period can last up to 6 months, and the overall study duration for participants is up to 36 months. Throughout the study, participants undergo a single study visit, with researchers monitoring tumor response using established criteria RECIST v1.1, progression-free survival, overall survival, and treatment toxicity. Safety and efficacy assessments include clinical and radiological evaluations, and exploratory research on tumouroids is conducted to optimize the functional assay. The study also tracks the feasibility of generating valid tumouroid reports and the time from referral to treatment start, contributing to personalized cancer care advancements.

CONDITIONS

Brief Title

Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here